Alpha-9 Theranostics

private

Alpha-9 Theranostics is a clinical stage, radiopharmaceutical company developing imaging and therapeutic molecules for solid and hematologic malignancies. Using proprietary technology and the Company’s expertise, these differentiated molecules have the potential to meaningfully extend patients’ lives with favorable safety profiles. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of improving the lives of patients affected by metastatic cancers.

CARGO Therapeutics

private

CARGO Therapeutics is engineering best-in-class CAR T-cell therapy to overcome resistance to cancer treatment and address barriers to access so that more patients may benefit from potentially curative therapies. CARGO is on a mission to outsmart cancer by advancing a new generation of best-in-class chimeric antigen receptor (CAR) T-cell therapies. Despite advances made by commercially available autologous CARs, these treatments are curative for fewer than half of all cancer patients. In addition, far too many patients are unable to access these potentially curative therapies due to other challenges, including manufacturing, supply constraints, slow turnaround time and reimbursement hurdles. The team at CARGO is intensely focused on pursuing novel solutions to achieve better cancer treatment outcomes and experiences.

A2 Biotherapeutics

private

A2 Biotherapeutics is an early-stage biotechnology company located in Southern California that develops novel medicines for serious illnesses.  We utilize an advanced targeting technology platform to increase the effectiveness of the body’s natural immune defenses. The company is funded by a syndicate of experienced biotechnology investors.

Alterome Therapeutics

private

Alterome Therapeutics is dedicated to advancing precision oncology through the creation of alteration-specific medicines. The company is leveraging a novel computational chemistry platform to target validated, high-value oncogenic drivers using small molecule inhibitors. Considered the gold standard approach in oncology, its targeted therapies home in on molecular characteristics unique to tumor drivers, which are absent from healthy cells, thereby limiting treatment-related toxicities and improving the therapeutic index for patients.

Ambagon Therapeutics

private

Ambagon Therapeutics is committed to aggressively expanding the boundaries of medicine through treatments that modulate some of the most challenging and potentially impactful targets identified across the proteome, with the goal of treating diseases that currently lack a cure and helping patients live longer and healthier lives. The team is developing a new class of medicines that can modulate previously undruggable targets and influence currently accessible ones in new ways. These small molecule stabilizers of 14-3-3:client complexes have the potential to address serious unmet needs in important therapeutic areas including cancer, metabolic disorders, neurodegenerative and infectious diseases.

Arrakis Therapeutics

private

Arrakis Therapeutics is a preclinical-stage biopharmaceutical company developing small-molecule drugs that directly bind to and modify the biological function of RNA to treat a wide array of diseases. Arrakis is pioneering the discovery of a new class of medicines called RNA-targeted small molecules, or rSMs. Arrakis’ proprietary platform enables the identification of structures and pockets within an RNA, finds drug-like compounds that bind these pockets, evaluates the biological impact of binding, and optimizes drug candidates. Arrakis was founded in 2015 and headquartered in Waltham, MA.

Arvinas, Inc.

public

Arvinas is a private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. Arvinas has developed a broad technology platform focused on high value targets, with the potential to deliver safer, more potent treatment than small molecule inhibitors, and to address the 75% of targets that evade inhibition and are currently undruggable. Arvinas’ therapeutic development is initially focused on developing degraders for high value targets in cancer, including androgen receptor and estrogen receptor.

Atavistik Bio

private

Atavistik Bio’s high-throughput platform for the unbiased identification of metabolite-protein interactions, will enable Atavistik to discover first-in-class drugs inspired and empowered by nature’s own mechanisms of allosteric control. The unique approach marries this validated platform with structure-aided drug design capabilities and cutting-edge insights into the regulation of metabolic systems—including clinical metabolomic data sets—to apply to genetically-validated targets in metabolic diseases and cancer.

Autolus Therapeutics plc

public

Focused on the treatment of cancer patients with precise, controlled and highly active engineered T-cell therapies. Autolus is a leader in cutting-edge T-cell therapies. Utilising advanced cell programming and manufacturing technologies, the company has established a development-stage pipeline of products for the treatment of haematological malignancies and solid tumours.

Black Diamond Therapeutics, Inc

public

Black Diamond Therapeutics is a next-wave cancer precision medicine company. Black Diamond pioneered the development of selective medicines for patients with genetically defined cancers driven by oncogenes activated by allosteric mutations. Led by an experienced management team Black Diamond has developed a computational and discovery platform with the aim to discover and validate new targets and develop novel approaches to creating highly selective therapeutics. Black Diamond’s first two disclosed programs are targeting groups of EGFR and HER2 allosteric mutants. Black Diamond was founded by David M. Epstein, Ph.D., Elizabeth Buck, Ph.D., and Versant Ventures, and is the first new company to emerge from Versant’s Ridgeline Discovery Engine in Basel, Switzerland. The company is located in Cambridge, Massachusetts and Basel, Switzerland.

Blueprint Medicines

public

Blueprint Medicines is a patient-driven oncology company developing highly selective kinase inhibitors for genomically-defined cancer subsets. Led by a management team and advisors with world-renowned expertise in cancer genomics, drug discovery and clinical oncology, Blueprint has developed a platform that combines genomics with a novel library of kinase inhibitors, enabling Blueprint to rapidly develop potent highly selective compounds against clear genomic driver targets. Blueprint Medicines was founded in 2011 and was initially financed by Third Rock Ventures and Fidelity Bioscience with corporate headquarters in Cambridge, Massachusetts.

Boundless Bio

private

Boundless Bio aims to treat the most aggressive cancers, which are frequently driven by ecDNA. The company’s initial therapeutic programs will pursue specific solid tumor types where ecDNA are highly prevalent. The company is also paving the way for a new understanding of extrachromosomal DNA, or ecDNA, one of the key drivers of the most aggressive cancers—specifically, those characterized by high copy number amplification of oncogenes. Building upon these insights, the company has  undertaken efforts to discover and develop proprietary treatments that exploit ecDNA’s unique vulnerabilities in precisely targeted patient populations.

C4 Therapeutics

public

C4 Therapeutics® is committed to transforming the treatment of cancer, neurological, and other important diseases with novel early stage therapies that eliminate disease-causing proteins. Our approach to medicine harnesses the innate machinery of the cell to attack disease and potentially bring deep and durable responses to patients.

Circle Pharma

private

Circle is developing a new paradigm for macrocycle drug discovery for cell-permeable molecules that can be delivered by oral administration. Circle’s macrocycle development platform is initially focusing its development efforts on intracellular protein-protein interactions that are key drivers in cancer. Its lead program targets cyclins A and E, which are part of the regulatory machinery that controls the progression of cells through the cell growth and division cycle.

Cleave Biosciences

private

Cleave Biosciences is a pioneer in the discovery and development of drugs that target protein homeostasis systems. Cleave’s CB-5083 is a first-in-class, oral inhibitor of p97, a critical enzyme that controls various aspects of protein homeostasis. P97 inhibition is a novel approach that has the potential to treat a wide range of cancers, including both solid tumors and hematologic malignancies. CB-5083 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of multiple myeloma.

Cullinan Oncology

public

Cullinan uniquely applies open innovation to the development of scientific  oncology assets. Their approach breaks down silos, encourages new ways of thinking and collaboration, and ultimately turns ideas and inspiration into novel executable therapeutic concepts. Through both internal and external means, they seek to develop first-in-class or best-in-class assets that have the potential to significantly improve the lives of those living with cancer.

EQRx

public

EQRx is committed to making innovative medicines at dramatically lower prices for the benefit of people and society. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before

Exo Therapeutics

private

Exo Therapeutics is a small molecule drug discovery and development company with a pioneering technology to address intractable pharmaceutical targets. By leveraging the company’s ExoSight™ platform, Exo is developing a deep pipeline of potent drug candidates that bind exosites, distal and unique binding pockets that have the potential to reprogram enzyme activity for precise and robust therapeutic effect. Through this specific and selective approach to challenging targets, Exo’s team of world-class researchers is unlocking breakthrough therapeutics in oncology, inflammation and a broad range of other diseases.

Flare Therapeutics

private

Flare is lighting up a new therapeutic space with an entirely different approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of their scientific founders, Flare’s team is leveraging the power of ‘switch sites’ as druggable regions that hold the control for predictable and profound changes in DNA transcription, and therefore, gene expression. Flare’s drug discovery to target ‘switch sites’ has rapidly advanced, resulting in its pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology.

IconOVir Bio

private

IconOVir Bio is a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer. The Company’s proprietary oncolytic virus platform is based on technology developed by scientific founder Clodagh O’Shea, Ph.D., of the Salk Institute. It is designed to address key limitations of first- and second-generation oncolytic viruses and provide a personalized therapy for cancer patients.

Ideaya Biosciences

public

IDEAYA is an oncology-focused biotechnology company committed to the discovery of personalized synthetic lethality medicines targeting DNA damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor microenvironment. Founded in 2015, the Company has assembled a world-class drug discovery team and a Scientific Advisory Board (SAB) which consists of industry thought leaders including members of the National Academy of Sciences and the National Academy of Medicine. IDEAYA is headquartered in South San Francisco, California.

IDRX

private

IDRx is a clinical-stage biopharmaceutical company dedicated to transforming cancer care with intelligently designed precision combination therapies. Inspired by a few curative combination regimens in cancer and the successful drug cocktails purposely engineered in other disease areas such as cystic fibrosis and antivirals, IDRx aims to address the limitations of today’s precision cancer medicines with highly selective, engineered drug combinations to stop key tumor escape mechanisms and prolong response to therapy. IDRx’s pipeline programs include small molecule tyrosine kinase inhibitors, IDRX-42 and IDRX-73, designed to inhibit key genetic drivers and drug-resistant mutations of gastrointestinal stromal tumor (GIST). Founded in 2021, IDRx’s leadership team has extensive experience in drug development and collectively has been involved in the discovery, development and commercialization of more than 10 approved drugs.

ITM Isotope Technologies Munich SE

private

ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including two phase III studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. By leveraging our nearly two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life.

Jounce Therapeutics

public

Jounce Therapeutics is a clinical stage immunotherapy company discovering and developing novel cancer immunotherapies designed to mobilize the immune system to seek out and attack cancerous cells and tumors. Jounce’s proprietary product engine has the potential to discover novel biological insights to drive the development of game-changing immunotherapy treatments with highly durable responses, extending and improving patients’ quality of life. Jounce is identifying product candidates from Next-generation T-cell checkpoint modulators and Tumor Microenvironment (TME) modifiers.

Kinnate Biopharma

public

Kinnate Biopharma Inc. is a private, early stage precision oncology company located in San Diego, CA. The company’s lead programs are small molecule kinase inhibitors that target known oncogenic genomically defined drivers.

Kronos Bio

public

Kronos Bio, located in San Mateo (CA, corporate headquarters) and Cambridge (MA, R&D), was built on over a decade of research into high-throughput screening strategies for chemical modulators of transcription factors and other recalcitrant targets in oncology. By combining small molecule microarrays (SMM) developed at MIT by Angela Koehler with know-how in biological assay development, Kronos technology platform enables high-throughput screens of chemical libraries against target proteins in cell lysates. As a result, a single screening assay can identify compounds that bind or interfere with the target protein activity directly, disrupt protein-protein complexes, or affect nearest neighbor proteins that may indirectly modulate target activity. This approach is suited for discovery of unique ligands that can be utilized in the generation of novel modulators or degraders of historically challenging targets such as transcription factors.

Kura Oncology, Inc.

public

Kura Oncology is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines for the treatment of solid tumors and blood cancers. Kura Oncology brings together a proven team of drug developers and biotech entrepreneurs. Kura Oncology’s diverse pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s approach to drug development is focused on rapidly translating novel science into life-saving medicines.

Laronde Bio

private

Laronde is building a company fueled by their modular Endless RNA™ (eRNA) platform, which will be supported by a large-scale digital and manufacturing infrastructure with the bold vision of 100 new medicines within the next decade. With eRNA, Laronde is making new therapeutics that will become essential medicines of the future.

MOMA Therapeutics

private

MOMA Therapeutics is a biotech company on a mission to discover the next generation of precision medicines by targeting the molecular machines that underlie diseases.

MOMA is bringing together drug discovery professionals and the tools to enable molecular machine drug discovery by exploiting a key vulnerability inherent to all enzymes in the class: their dependence on well-coordinated, stepwise changes in protein confirmation.

Neon Therapeutics

acquired

Neon Therapeutics is a leading company in the development of neoantigen based cancer therapies. Their programs are designed to leverage multiple facets of the immune response to elicit potent immune attack of tumors, with the aim of providing durable response to patients in need. Neon Therapeutics’ lead program, NEO-PV-01, a personalized neoantigen vaccine, has entered clinical development with a first study in combination with Opdivo (nivolumab) in patients with metastatic melanoma, non-small cell lung cancer and bladder cancer.

Peloton Therapeutics

acquired

Founded by Professor Steven L. McKnight, Chairman of Biochemistry at The University of Texas Southwestern Medical Center (UT Southwestern), Peloton Therapeutics represents a unique combination of innovative science, talented researchers, and seasoned investors and management. Working in close collaboration with scientists at UT Southwestern, Peloton is advancing a promising discovery and development pipeline comprised of small-molecule programs, each with a distinct target and mechanism of action. The Company’s vision is to become a major biotech presence in Dallas by leveraging great science, high-caliber people, and the long-term support of Texas-based research institutions.

PMV Pharma

public

PMV Pharma, located in Cranbury (NJ) was built on over three decades of research into p53 biology and has gained unique insights into the discovery of selective modulators of p53 and its pathways. p53, also called “guardian of the genome”, is one of the most commonly mutated proteins in human cancers and enables cancer cells to escape death. The company’s pathway modulators are small molecule drugs with a unique mechanism of action, which promises to restore p53 to its normal function, eliminating the escape route and selectively killing mutant cancer cells without affecting normal tissues.

Revolution Medicines

public

Revolution Medicines is an innovative and dynamic organization of expert scientists and business executives working together to discover and develop new medicines for cancer patients against frontier oncology targets. Frontier oncology targets are proteins that drive the growth of cancers or that control immune responses that can defeat them. Frontier targets have not been drugged successfully before or have been inadequately served by previous drug discovery efforts. The current discovery programs are focused in two areas, our Phosphatase and Beyond Rule of 5 (bRo5) Platforms.

Scorpion Therapeutics

private

Scorpion Therapeutics was founded to broaden the reach and impact of precision medicine to more people with cancer. The company is integrating cutting-edge technologies across target discovery, medicinal chemistry, and translational medicine to deliver Precision Oncology 2.0. Scorpion’s experienced leadership team is executing a fit-to-purpose model to efficiently unlock the next generation of precision oncology.

Silverback Therapeutics

public

Developing a new generation of systemically delivered, locally active therapies that potently modulate fundamental disease pathways once deemed inaccessible.

Theseus Pharmaceuticals

public

Theseus is advancing cancer care by developing next-generation therapies to address treatment resistance. Leveraging the team’s deep expertise in developing targeted cancer therapies, Theseus is addressing the challenge of drug resistance by developing the next generation of tyrosine kinase inhibitors (TKIs).

Turning Point Therapeutics, Inc.

public

TP Therapeutics is a structure-based drug design company for the discovery and development of precision medicines for cancer. The company was founded on October 2013 based on research conducted by Jean Cui, TP’s Founder and Chief Scientific Officer and is focusing on the design of novel chemical identities for established oncogene drivers with secondary resistant mutations. TP Therapeutics is headquartered in San Diego, California.

TYRA Biosciences

public

Tyra Biosciences is a biotechnology company targeting acquired resistance in oncology with purpose-built drugs. A proprietary in-house discovery platform enables TYRA Biosciences to see the real-world interaction between drug and target in rapid, sequential, structural SNÅPshots. With each SNÅP, the company brings speed, clarity, and focus to structure-based drug design.

Vividion Therapeutics

acquired

Vividion Therapeutics is a biopharmaceutical company founded in 2014 and headquartered in San Diego, CA. Vividion is a preclinical-stage biotech company focused on discovering small-molecule drugs that treat major unmet clinical needs using the first platform for proteome-wide ligand and target discovery. The company’s cutting-edge platform was spun out of the labs of Vividion’s scientific founders Ben Cravatt and Phil Baran, a team of highly innovative and very knowledgeable experts in chemical biology and synthetic chemistry from The Scripps Research Institute in La Jolla, CA. Vividion is committed to advancing and applying its pioneering synthetic and proteomic chemistry platforms to create therapeutics that will make a transformative difference in patients.